Cancer clinical trials in the region Pays de la Loire
432 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Breast cancer
#NCT06103864
#2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3
Breast cancer
#NCT06103864
#2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
8 recruiting sites
AstraZeneca
Phase 3
Colon cancer
Rectal cancer
Anal cancer
Pancreas cancer
Liver and bile duct cancer
Stomach and esophageal cancer
Small intestine and appendix cancer
#NCT07087054
#2024-519875-24-00
Required histologic types
Ileum cancer
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
None
6 recruiting sites
Crinetics Pharmaceuticals Inc.
Phase 3
Colon cancer
Rectal cancer
#NCT07228832
#2025-521587-35-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF
MSI/dMMR
Excluded previous treatments at localized stage
Immunotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Targeted therapy
8 recruiting sites
Summit Therapeutics
Phase 3
Lymphoma
CLL & Richter's syndrome
#NCT06104566
#2023-508005-24-00
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
12 recruiting sites
Ascentage Pharma Group Inc.
Phase 3
Breast cancer
#NCT05696626
#2023-503708-10-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Hormone therapy
Excluded genetic anomalies
Other mutation
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Sermonix Pharmaceuticals Inc.
Phase 3
Amyloidosis
#NCT07207811
#2024-518899-31-00
Required histologic types
Other
Required organ involvement status
Presence
Required organ involvements
Cardiac
19 recruiting sites
Novo Nordisk A/S
Phase 3
Brain tumors / Central nervous system tumors
#NCT05904119
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery
Radiochemotherapy
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07213804
#2025-522255-25-00
Partie A (Résistant au platine)
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required platino resistance
Recurrence within 6 months after platinum-based tr...
Required previous treatments at localized stage
Chemotherapy
Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Eli Lilly et compagnie
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT07213804
#2025-522255-25-00
Partie B (Sensible au platine avec traitement antérieur par Parpi)
Required histologic types
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at localized stage
Chemotherapy
Targeted therapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
10 recruiting sites
Eli Lilly et compagnie